Search PubMed⌕ Search

Biomedical subjects

N A Krupina

Publications and source records attributed to N A Krupina.

At least 19 recordsLinked to original sources

Immunization of rats with conjugates of dopamine and serotonin with bovine serum albumin prevents the development of experimental MPTP-induced depressive syndrome (electrophysiological parameters).

Electrophysiological experiments on Wistar rats demonstrated that prior immunization of animals with conjugates of dopamine and serotonin with bovine serum albumin, as well as with bovine serum albumin alone, played a partial protective role in relation to the subsequent development in these animals of experimental MPTP-induced depressive syndrome: immunized animals showed no signs of the depressive state such as decreases in the latency of onset of REM sleep and the development of epileptiform activity in the caudate-putamen complex, though the increase in the proportion of REM sleep in the overall structure of sleep persisted. Changes in the spectral characteristics of brain electrical activity and sleep structure during the development of experimental MPTP-induced syndrome in animals immunized with conjugates of dopamine and serotonin with bovine serum albumin and with bovine serum albumin alone were antigen-specific and reflected functional shifts in the activity of those neurotransmitter systems targeted by immunization, as well as others sensitive to changes in the body's immunological status.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗

[Insufficiency of nigrostriatal dopaminergic system as a disregulation mechanism of dopamine-dependent depression syndrome].

Considered here, is a role of insufficiency of central dopaminergic systems in the pathogenesis of depression. Experimental data have been obtained in a rat model of depression-like syndrome caused by administration of specific-for-dopamine-neurons neurotoxin 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine. Along with literature data, these results suggest a reduction of dopaminergic system activity in striatum, accompanied by the latter's hyperactivation, as a pathophysiological mechanism for development of certain depressive disorders.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗

Experimental depressive-pain syndrome in rats with initial various anxiety-phobic levels: a behavioral study.

Modeling of neurogenic pain syndrome by sciatic nerve transection in rats with pronounced dopamine-deficiency-dependent 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-induced experimental depressive syndrome forms a stable state of combined pain and depression, which can be considered as a model of the pain-depressive syndrome. The neurogenic pain syndrome prolongs the state of behavioral depression in rats irrespective of their initial anxiety level. The depressive symptoms can potentiate the severity of pain syndrome. By a number of indices, more pronounced behavioral changes during the development of pain-depressive syndrome occur in initially nonanxious rats.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗

Count and phagocytic activity of leukocytes in rats with experimental depressive syndrome caused by systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Leukocyte count decreased, relative content of neutrophils and monocytes increased, and their phagocytic activity was suppressed in rats with 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-induced depressive syndrome at the stage of acute behavioral depression. The severity of behavioral depression inversely correlated with changes in the absolute neutrophil and monocyte counts.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗

[A new natural model of elevated anxiety in rats].

The levels of anxiety were determined in male Wistar rats using a complex multiparameter method for evaluating anxiety-phobic states in rats based on ranged scale. The effects of psychotropic drugs differed in rats with innate high and low levels of anxiety. Anxiolytics sodium valproate (200 mg/kg), phenazepam (0.05 mg/kg) and diazepam (0.1 and 0.6 mg/kg) reduced anxiety in rats with innate high level of anxiety and prevented increase of anxiety induced by saline in rats with innate low level of anxiety. Pentylenetetrazol (10 mg/kg) and haloperidol at a large dose (0.5 mg/kg) increased anxiety in rats with either high or low innate levels of anxiety. However sodium lactate (600 mg/kg) increased anxiety only in rats with innate high level of anxiety. Haloperidol at a small dose (0.01 mg/kg) and melipramin (10 mg/kg) were uneffective in rats with innate high level of anxiety. Results believed the rats with innate high level of anxiety to be used as a new natural animal model of anxiety.

Animals↗